CausalSentinel

Protein Dossier — JAK2 (Tyrosine-protein kinase JAK2)

MR feasibility tier: A — Published pQTL-MR estimates exist for this protein (retrieved below - not computed here).

1. Published MR estimates (retrieved, not computed)

Outcome beta se p method nSNP cis/trans coloc
Eye problems or disorders: Glaucoma 0.262 0.0678 1.09e-04 Wald ratio 1 trans NA
Eye problems or disorders: Injury or trauma resulting in loss of vision 0.362 0.0965 1.72e-04 Wald ratio 1 trans NA
Diagnoses - main ICD10: K60 Fissure and fistula of anal and rectal regions 0.394 0.106 1.99e-04 Wald ratio 1 trans NA
Squamous cell lung cancer -0.448 0.128 4.65e-04 Wald ratio 1 trans NA
Forced vital capacity (FVC) 0.027 0.00861 0.00172 Wald ratio 1 trans NA
Packed cell volume -0.296 0.112 0.00814 Wald ratio 1 trans NA
Haemoglobin concentration -0.0973 0.037 0.00848 Wald ratio 1 trans NA
Height 0.0382 0.0157 0.015 Wald ratio 1 trans NA
Percent emphysema -0.0965 0.0416 0.0205 Wald ratio 1 trans NA
Forced expiratory volume in 1-second (FEV1) 0.0208 0.00908 0.0218 Wald ratio 1 trans NA
Non-cancer illness code self-reported: diverticular disease or diverticulitis -0.311 0.139 0.0246 Wald ratio 1 trans NA
Serum creatinine (eGFRcrea) 0.00935 0.00425 0.0278 Wald ratio 1 trans NA
…and 84 more outcomes (see JSON)              

2. pQTL instrument availability (Tier-B probe)

Dataset Trait Author Year
prot-c-4998_50_1 JAK2 Suhre K 2019

3. GWAS Catalog results — traits with signal at this locus

346 association rows across 160 traits (325 genome-wide significant rows). Associations are loci, not causal claims; the mapped gene at a locus is not necessarily the effector gene.

Trait best p lead SNP n assoc study MR status
Myeloproliferative disease (PheCode 200) 1e-323 rs77375493 4 GCST90475608 no MR -> candidate analysis
Polycythemia vera (PheCode 200.1) 1e-323 rs77375493 3 GCST90479825 no MR -> candidate analysis
red cell diameter width (RDW, mean, inv-norm transformed) 1e-323 rs77375493 3 GCST90476361 no MR -> candidate analysis
red cell diameter width (RDW, maximum, inv-norm transformed) 9e-308 rs77375493 3 GCST90476357 no MR -> candidate analysis
red cell diameter width (RDW, minimum, inv-norm transformed) 2e-264 rs77375493 3 GCST90476365 no MR -> candidate analysis
platelet count (maximum, inv-norm transformed) 5e-234 rs77375493 2 GCST90480650 no MR -> candidate analysis
Other diseases of blood and blood-forming organs (PheCode 28 2e-199 rs77375493 3 GCST90479994 no MR -> candidate analysis
monocyte (fraction, mean, inv-norm transformed) 8e-171 rs77375493 3 GCST90475511 no MR -> candidate analysis
red blood cell count (RBC, maximum, inv-norm transformed) 4e-165 rs77375493 3 GCST90476345 no MR -> candidate analysis
white blood cell count (WBC, mean, inv-norm transformed) 2e-160 rs77375493 3 GCST90476454 no MR -> candidate analysis
mean corpuscular hemoglobin concentration (MCHC, minimum, in 1e-157 rs77375493 3 GCST90475462 no MR -> candidate analysis
lymphocyte (fraction, mean, inv-norm transformed) 8e-155 rs77375493 3 GCST90475435 no MR -> candidate analysis
…and 148 more traits (see JSON)          

4. Phenome map — where this gene is a genetic locus, vs. where MR exists

Top diseases by Open Targets association (of 1636 total). Associations are loci, not causal claims. The causal-status column is a four-state triage per pair: established (curated) = a curated clinical assertion exists (ClinGen/G2P/GEL/Orphanet/ClinVar — any validity level, MR adds little); exploratory rare-variant signal = ExWAS burden evidence without curation — a candidate NEW gene-disease relationship; common-variant locus = GWAS signal, classic pQTL-MR territory; multi-layer = burden+GWAS together, an allelic-series candidate (the strongest causal setup). Burden estimand is carrier-vs-noncarrier, not per-SD MR.

Disease genetic assoc. burden (ExWAS) causal status MR status
acquired polycythemia vera 0.784 0.758 established (curated) no MR -> candidate analysis
primary myelofibrosis 0.642 0.249 established (curated) no MR -> candidate analysis
ulcerative colitis 0.818 common-variant locus no MR -> candidate analysis
myeloproliferative disorder 0.68 0.713 established (curated) no MR -> candidate analysis
Crohn disease 0.807 common-variant locus no MR -> candidate analysis
neoplasm 0.647 0.76 established (curated) MR: beta=0.166, p=0.134 (trans)
Splenomegaly 0.79 0.865 established (curated) no MR -> candidate analysis
acute myeloid leukemia 0.743 established (curated) no MR -> candidate analysis
cancer 0.654 common-variant locus MR: beta=-0.448, p=4.65e-04 (trans)
essential thrombocythemia 0.377 established (curated) no MR -> candidate analysis
thrombocythemia 3 0.826 established (curated) no MR -> candidate analysis
hematologic disorder 0.81 0.824 multi-layer: burden+GWAS (allelic-series candidate) no MR -> candidate analysis
ankylosing spondylitis 0.492 common-variant locus MR: beta=-0.465, p=0.207 (trans)
hemorrhagic disease 0.751 0.76 multi-layer: burden+GWAS (allelic-series candidate) no MR -> candidate analysis
Hepatomegaly 0.707 0.753 multi-layer: burden+GWAS (allelic-series candidate) no MR -> candidate analysis

Of the 15 rows above, 12 have no MR estimate in this resource. Across all retrieved diseases for this gene: 1 exploratory rare-variant signal(s), 3 multi-layer (allelic-series candidate) pair(s). Final triage still belongs to a statistical geneticist.

5. Downstream annotation (druggability & safety preview)

Layer Result
ChEMBL druggability 20 known modulators (Tyrosine-protein kinase JAK2)
gnomAD constraint pLI=1.2e-16, LOEUF=0.739 — LoF-tolerant
GWAS Catalog 103 unique SNPs / 217 rows
ClinVar 796 records; 7 pathogenic in sample of 30
PharmGKB/ClinPGx no annotations

Caveats declared by the tools

Sources

Provenance